Abstract: Linsitinib (OSI-906) is an orally bioavailable, small-molecule dual inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) and the insulin receptor (IR). While initially investigated as an antineoplastic agent, linsitinib is currently being repositioned as a promising targeted therapy for Thyroid Eye Disease (TED), also known as Graves' Orbitopathy (GO). By suppressing the PI3K/Akt and ERK signaling pathways, linsitinib effectively inhibits cellular proliferation, adipogenesis, and hyaluronic acid secretion in orbital fibroblasts. Recent Phase 2b/3 clinical trials have demonstrated its clinical efficacy, showing a significant reduction in proptosis with a favorable safety profile, notably lacking the hearing dysfunction associated with other IGF-1R inhibitors. Although its dual inhibition of the insulin receptor presents a risk of metabolic side effects such as hyperglycemia, its oral administration route and potent anti-inflammatory and anti-fibrotic properties make it a highly attractive candidate for the future medical management of TED.
1. Introduction
Thyroid Eye Disease (TED), or Graves' Orbitopathy (GO), is a complex, immune-mediated disorder characterized by inflammatory dysregulation and remodeling of the periorbita and orbit [2]. The pathogenesis involves the activation of orbital fibroblasts, leading to connective tissue remodeling, orbital fat expansion, and extraocular muscle enlargement, which clinically manifest as proptosis, diplopia, and potential optic nerve dysfunction [2]. The functional crosstalk between the thyrotropin receptor (TSHR) and the insulin-like growth factor 1 receptor (IGF-1R) on orbital fibroblasts is a critical trigger for this inflammatory cascade [1][2].
While monoclonal antibodies targeting IGF-1R, such as teprotumumab, have emerged as effective therapies for TED, they are administered intravenously and have been associated with adverse effects, including irreversible sensorineural hearing loss [1][2]. Linsitinib (OSI-906) is an emerging oral small-molecule kinase inhibitor of both IGF-1R and the insulin receptor (IR) [1][3]. Originally developed and evaluated in clinical trials for advanced solid tumors [5], linsitinib is now being actively investigated as a targeted, orally administered immunotherapy for the management of TED [1][2].
2. Pharmacological Activity
In preclinical mouse models of TED, linsitinib effectively prevented the development and progression of Graves' Orbitopathy by reducing macrophage and T cell infiltration, inflammation, and adipogenesis [1]. It has been shown to inhibit IGF-1-induced cellular proliferation and hyaluronic acid (HA) secretion in orbital fibroblasts derived from patients with TED [1].
Clinically, the efficacy and safety of linsitinib were evaluated in a Phase 2b/3, multicenter, randomized, double-masked, placebo-controlled study (the LIDS clinical trial, NCT05276063) involving 90 patients with active moderate-to-severe GO [1][2]. Patients received either linsitinib (75mg or 150mg twice daily) or a placebo for 24 weeks. Topline results revealed that linsitinib at 150mg twice daily achieved a significant proptosis response rate of 52% at week 24 (p = 0.01) [1].
Beyond its application in TED, linsitinib exhibits significant pharmacological activity in oncology. It suppresses tumor growth in IGF-1R-driven xenograft models [3][5]. Furthermore, linsitinib has been shown to overcome multidrug resistance (MDR) in cancer cells by antagonizing ATP-binding cassette (ABC) transporters, specifically ABCG2 and ABCC10, thereby potentiating the effects of antineoplastic drugs like mitoxantrone, SN-38, paclitaxel, docetaxel, and vinblastine [3].
3. Molecular Mechanism of Action
Linsitinib functions as a selective, dual inhibitor of IGF-1R and IR autophosphorylation [3][4][5]. In the context of TED, TSH-R and IGF-1R are overexpressed in GO orbital fibroblasts (GO-OF) and form a physical and functional complex (a signalosome) where beta-arrestin 1 acts as a scaffold to mediate receptor crosstalk [1]. Simultaneous activation of both receptors synergistically increases hyaluronic acid secretion [1].
By inhibiting IGF-1R kinase activity, linsitinib suppresses downstream intracellular signaling cascades, notably the phosphatidylinositol 3-kinase (PI3K)/Akt and extracellular signal-regulated kinase (ERK) pathways [1]. This blockade inhibits cellular proliferation and HA secretion. Additionally, in vitro studies demonstrate that linsitinib induces apoptosis and inhibits the proliferation of target cells expressing both IGF-1R and TSH-R [1]. In metabolic and oncological models, linsitinib has also been shown to diminish the phosphorylation of downstream targets including p70S6K, S6 protein, 4EBP-1, GSK3beta, and AMPK [4].
In its role as an MDR reversal agent, linsitinib attenuates ABCG2- and ABCC10-mediated drug efflux by directly inhibiting the transport function of these proteins, rather than altering their protein expression levels [3].
4. Structure-Activity Relationship (SAR)
While the provided literature does not detail the specific chemical structure modifications or comprehensive Structure-Activity Relationship (SAR) data for linsitinib, it is structurally classified as a small-molecule tyrosine kinase inhibitor [1][3]. Unlike monoclonal antibodies (such as teprotumumab or VRDN-001) that bind to the extracellular alpha subunit of IGF-1R [2], linsitinib is a small molecule that penetrates the cell and targets the intracellular kinase domains of both IGF-1R and the insulin receptor [1][3]. This dual-targeting capability at the kinase level is responsible for both its potent efficacy in halting IGF-1R/TSH-R crosstalk and its specific metabolic side effect profile [1][4].
5. Current Limitations
A primary limitation of linsitinib arises from its dual inhibition of the insulin receptor (IR), which can induce acute insulin resistance and metabolic disturbances. In murine models, daily administration of OSI-906 provoked hyperinsulinemia, glucose intolerance, lipodystrophy, and hepatic steatosis, alongside increased beta-cell mass and proliferation [4]. In human clinical trials for solid tumors, hyperglycemia was a noted adverse effect, occurring more frequently in diabetic cohorts [5]. Similarly, in the Phase 2b/3 TED trial, 1 out of 29 patients (3%) developed hyperglycemia, though it required no intervention [1]. Fortunately, studies indicate that metabolic side effects, such as hyperglycemia and liver steatosis, are reversible upon withdrawal of the drug [4].
Another pharmacological limitation observed in vitro is that while linsitinib fully antagonizes hyaluronic acid secretion induced by low concentrations of the TSH-R stimulating antibody M22, its efficacy diminishes at high concentrations of M22 [1].
6. Future Perspectives
The future of linsitinib in the management of Thyroid Eye Disease is highly promising. A confirmatory Phase 3 clinical study is scheduled to commence in 2025 [1]. The distinct advantage of oral administration, combined with its proven clinical efficacy in reducing proptosis and a favorable safety profile—specifically the absence of drug-related hearing dysfunction seen with intravenous IGF-1R antibodies—makes linsitinib an attractive therapeutic option for patients with GO [1].
Furthermore, preclinical evidence suggests that combining linsitinib with a TSH-R antagonist (such as ANTAG3) synergistically suppresses hyaluronic acid secretion in orbital fibroblasts [1]. This indicates that dual-targeted combination therapies could be a future strategy to overcome the diminished efficacy of linsitinib in the presence of high autoantibody concentrations. Additionally, linsitinib's ability to inhibit ABC transporters positions it as a potential supplementary agent in traditional cancer chemotherapy to overcome multidrug resistance [3].
